The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | The current status of CAR T-cell therapy for lymphoma in the UK
In this video, Andrea Kuhnl, MD, King’s College Hospital, London, United Kingdom, briefly outlines the current status of CAR T-cell therapy for lymphoma in the United Kingdom, noting that axicabtagene ciloleucel (axi-cel) is the only approved CAR-T product for patients. Axi-cel is available for use in the second and third-line settings, and Dr Kuhnl anticipates the approval of lisocabtagene maraleucel (liso-cel) in the near future. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We currently only have access to axi-cel for large B-cell lymphoma in the UK, both for the third line and second line treatment. So second line for those being deemed fit for autologous transplant and relapsing within 12 months. The majority of patients would get second line CAR-T because we see less and less late relapses, but of course patient groups who are currently not included in second-line eligibility like primary mediastinal B-cell lymphoma, Richter’s transformation, or those not deemed fit for transplant these patients would get a third-line CAR-T...
We currently only have access to axi-cel for large B-cell lymphoma in the UK, both for the third line and second line treatment. So second line for those being deemed fit for autologous transplant and relapsing within 12 months. The majority of patients would get second line CAR-T because we see less and less late relapses, but of course patient groups who are currently not included in second-line eligibility like primary mediastinal B-cell lymphoma, Richter’s transformation, or those not deemed fit for transplant these patients would get a third-line CAR-T. And we do expect to hear back soon regarding access to liso-cel in the UK which we hope will come our way soon.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Kite Gilead, Roche, Abbvie, BMS; Honoraria: Kite Gilead, Astra Zeneca.
